Krystal Biotech, Inc. (KRYS) Cash Flow Statement
Krystal Biotech, Inc. (KRYS) generated $272.3M of operating cash flow over the twelve months to 2026-06-30, spent $14.6M on capital expenditure and had free cash flow of $257.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRYSKrystal Biotech, Inc.Follow KRYS — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- 39.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.09 | 0.12 | 0.20 | 0.27 | |
| Capital expenditure | 0.01 | 0.00 | 0.01 | -0.01 | |
| Free cash flow | -0.10 | 0.12 | 0.19 | 0.26 | |
| Stock-based compensation | 0.04 | 0.05 | 0.05 | — |
USD billions · SEC XBRL
Krystal Biotech, Inc. — questions
- What is Krystal Biotech, Inc.'s operating cash flow?
- $272.3M over the twelve months to 2026-06-30.
- How much does Krystal Biotech, Inc. spend on capital expenditure?
- $14.6M over the twelve months to 2026-06-30.
- What is Krystal Biotech, Inc.'s free cash flow?
- $257.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Krystal Biotech, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.